Kiniksa Pharma posts Q3 revenue of $286 M and lifts 2026 ARCALYST sales outlook to $1.045‑$1.050 B
Kiniksa Pharmaceuticals International reported third‑quarter 2026 revenue of $286.0 million, up about 58% year‑over‑year, and net income of $47.3 million. The company raised its 2026 ARCALYST net product revenue guidance to $1.045 billion‑$1.050 billion, up from the prior $980 million‑$995 million range. It also noted progress on its pipeline, with Phase 3 data for KPL‑387 expected in the second half of 2027 and a Phase 1 trial for KPL‑1161 planned by year‑end.
Why it matters
The higher ARCALYST outlook signals stronger than expected sales growth, which should boost 2026 revenue and cash‑flow expectations (the company says its operating plan will remain cash‑flow positive). Analysts and investors may reprice the stock based on the upgraded guidance, as reflected by a 19.4% share price jump after the release.
Key facts
- 1Q3 2026 total revenue was $286.0 million, up from $180.9 million in Q3 2025. stocktitan.net
- 2Q3 2026 net income was $47.3 million, compared with $18.4 million a year earlier. stocktitan.net
- 3ARCALYST net product revenue for the quarter was $286.0 million. stocktitan.net
- 4Kiniksa raised its 2026 ARCALYST net product revenue guidance to $1.045 billion‑$1.050 billion, up from $980 million‑$995 million. stocktitan.net
- 5Phase 3 pivotal trial data for KPL‑387 are expected in the second half of 2027. stocktitan.net
- 6The company plans to start a Phase 1 trial of KPL‑1161 by the end of 2026. stocktitan.net
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.